Cloverleaf.me, Inc. – Trademark Portfolio
Entity Type: 03
Cloverleaf.me, Inc. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 5 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 3 trademarks are registered and 3 are pending. Notable registered marks include 16 TYPES and CLOVERLEAF. The owner is based in Cincinnati, OH.
310 Culvert Street
Suite 301
Cincinnati, OH 45202
Showing of trademarks Trademarks
Trademark Classifications
Cloverleaf.me, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Cloverleaf.me, Inc. have?
Cloverleaf.me, Inc. has 8 U.S. trademarks filed with the USPTO. Of these, 3 registered, 3 pending, 2 abandoned.
What trademark classes does Cloverleaf.me, Inc. file in?
Cloverleaf.me, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are Cloverleaf.me, Inc.'s most well-known trademarks?
Cloverleaf.me, Inc.'s registered trademark portfolio includes well-known marks such as 16 TYPES and CLOVERLEAF. These are among 3 currently registered trademarks in the portfolio.
What is Cloverleaf.me, Inc.'s trademark registration success rate?
Cloverleaf.me, Inc. has a 60% trademark registration rate, with 3 out of 5 resolved applications resulting in successful registration. Currently, 3 applications are pending review.